New Report on "Nonalcoholic Steatohepatitis – Drug Pipeline Analysis and Market Forecasts to 2016" added in Vision Shopsters



GlobalData’s report, “Nonalcoholic Steatohepatitis (NASH)- Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global nonalcoholic steatohepatitis market. The report identifies the key trends shaping and driving the global nonalcoholic steatohepatitis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global nonalcoholic steatohepatitis sector. GlobalData estimated that the Nonalcoholic Steatohepatitis (NASH) market was worth $1.8 billion in 2009. The major reason for the limited market revenues is that there is no approved drug for the treatment of NASH. NASH is an unrecognized cause of cryptogenic cirrhosis with emerging importance. It is a more aggressive form of NAFLD (Nonalcoholic Fatty Liver Disease), which often progresses to liver cirrhosis. The increased prevalence of diabetes, obesity and hyperlipidemia are considered to be important causes of NASH. Antioxidants, anti-diabetic medications, anti-obesity medications and antihyperlipidemics are some of the off-label products currently used by NASH patients. The modest growth forecast is primarily attributed to a weak pipeline landscape. Due to the fact that low diagnosis rates, low prescription rates and low treatment seeking rates continue to pose significant challenges for prospective market entrants, the market landscape in future is expected to remain static without any significant dynamism.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.


The scope of the report includes:

  • Annualized global nonalcoholic steatohepatitis market revenue data from 2001 to 2009, forecast for seven years to 2016.

  • Key geographies covered in this report include the US (the United States), the UK (the United Kingdom), Italy, Spain, Germany, France and Japan.

  • Pipeline analysis data providing a split across the different phases of development by mechanism of action and emerging trends. The key classes of mechanism of action include dietary supplements, enzyme inhibitors, PPAR (peroxisome proliferator-activated receptor) gamma selective agonists, combination therapies, cholesterol Inhibitors, CB-1 cannabinoid receptor antagonists, angiotensin II receptor antagonists, lipid peroxidation inhibitors, glutathione enhancers and immunologic drugs.

  • Analysis of the current and future market competition in the global nonalcoholic steatohepatitis market. Key market players covered are Raptor Pharmaceuticals, Gilead Sciences, Axcan Pharma, Eli Lilly & Company and Enzo Biochem.

  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with NASH.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of the pipeline products and technologies and by identifying the companies with the most robust pipelines.

  • Develop business strategies by understanding the trends shaping and driving the global NASH market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global NASH market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

  • What’s the next big thing in the global NASH market landscape? – identify, understand and capitalize.

Companies Mentioned

Raptor Pharmaceuticals
Gilead Sciences
Eli Lilly and Company
Enzo Biochem

To know more about this report & to buy a copy please visit :

Contact us:

Ph : 91-22-40583000
Website :


Source by Visionshopsters